ClinicalTrials.gg
CompletedNCT00650845RESCUEUpdated Jun 9, 2015Results posted

Renal Safety Evaluation After Dotarem®-Enhanced MRI

A Phase 4 interventional study of Dotarem®-enhanced MRI and non-enhanced MRI in Renal Insufficiency, sponsored by Guerbet. Completed at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-09.

Sponsored by Guerbet · Phase 4, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
135
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 107 studies in Renal Insufficiency with a site in France — 13 open to participants now, 16 under way, none of them phase 3. Renal Insufficiency · France.

Enrollment
30th of 67
135 · median 108
Started
2008
with 8 others
Phase 4
8 of 107
none open now
Registered
11th of 107
by date

Among the 107 studies in Renal Insufficiency with a site in France, this one is the 30th largest by enrollment of the 67 interventional ones that give a count, is one of 9 that started in 2008, is one of 8 in phase 4, and was the 11th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

13 of the 107 studies in Renal Insufficiency with a site in France are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Renal Insufficiency with a site in France, or all of them as a file.
02

Study summary

Although there is a well documented risk of acute renal failure with the iodinated contrast agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity remains controversial. The aim of this study was to evaluate the safety profile of gadoterate meglumine (Dotarem®) in patients with chronic renal insufficiency by evaluating the rate of patients experiencing contrast-induced nephrotoxicity following the injection of gadoterate meglumine.

Read the detailed description

Patients with renal insufficiency not requiring hemodialysis and scheduled to undergo a contrast enhanced MRI or unenhanced MRI examination to specify a diagnosis, were selected for inclusion. Two groups of patients were defined on the basis of the planned imaging procedure selected to obtain a diagnosis: those undergoing a Dotarem®-enhanced MRI and those undergoing an unenhanced MRI.

A clinically significant increase in serum creatinine levels after the contrast-enhanced MRI exam was used as an indication of contrast induced nephrotoxicity. A blood test was performed 24h before the MRI in order to evaluate baseline creatinine values. 72h after the exam, a second blood test was performed. An increase in creatinemia above 25% from baseline levels was defined as a contrast-induced nephrotoxic reaction. The primary endpoint of the study assessed the percentage of patients presenting a contrast-induced nephrotoxic reaction in order to show a non inferiority of enhanced as compared to non-enhanced MRI exams.

03

Conditions studied

  • Renal Insufficiency

Browse trials for

Keywords

  • contrast-induced nephropathy, creatinemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, > or equal 18 years ;
  • Patient with a known stable renal insufficiency ;
  • Patient scheduled to undergo an MRI examination to specify a diagnosis ;
  • Patient able to understand and provide written to participate in the trial ;

Exclusion criteria

Exclusion Criteria:

  • Patient with a to MRI ;
  • Patient who has a diagnosis of an hemodynamic instability or acute myocardial infarction within 15 days prior the inclusion ;
  • Patient who needs hemodialysis ;
  • Patient with known allergy to gadolinium chelates ;
  • Patient receiving medications known to be nephrotoxic or to cause increases in serum creatinine level within 2 weeks before the inclusion ;
  • Patients planned to either undergo surgery or receive chemotherapy ;
  • Any condition which, based on the investigator's clinical judgement, would prevent the patient from completing all trial assessments and visits ;
  • Patient under guardianship and/or inability or unwillingness to cooperate with the requirements of this trial ;
  • Patient with newly discovered unstable diabetes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Dotarem®-enhanced MRI

    Patients undergoing Dotarem®-enhanced MRI for diagnostic purposes

    Drug: Dotarem®-enhanced MRI

  • Other
    Non-enhanced MRI

    Patients undergoing non-enhanced MRI for diagnostic purposes

    Other: non-enhanced MRI

Interventions

  • Single IV administration before MRI exam

    Also known as: Gadoterate meglumine, Gadoteric acid

  • Othernon-enhanced MRI

    non injected MRI

    Also known as: unenhanced MRI

06

What researchers measure

Primary outcomes

  1. Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis Set Population.

    Comparing the number of patients experiencing an increase of creatinine of at least 25% over baseline levels after Dotarem®-enhanced MRI and after non-enhanced MRI in patients with at least a moderate renal insufficiency.

    Time frame: baseline pre MRI and 3 days post MRI

  2. Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of at Least 25% Over Baseline Levels, in the Per Protocol Population.

    Comparing the number of patients experiencing an increase of creatinine of at least 25% over baseline levels after Dotarem®-enhanced MRI and after non-enhanced MRI in patients with at least a moderate renal insufficiency.

    Time frame: Baseline pre MRI and 3 days post MRI

Secondary outcomes

  1. Percent Change of Serum Creatinine Level From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population.

    Serum creatinine levels were measured at baseline and at 72±24 hours after examination. The percentage of change in creatinemia from baseline was calculated for both the Dotarem® and the non-enhanced groups.

    Time frame: Baseline pre MRI and 3 days post MRI

  2. Percent Change of Serum Creatinine Level Variation From Baseline to 72±24 Hours After Examination, in the Per Protocol Population

    Serum creatinine levels were measured at baseline and at 72±24 hours after examination. The percentage of change in creatinemia from baseline was calculated for both the Dotarem® and the non-enhanced groups.

    Time frame: Baseline pre MRI and 3 days post MRI

  3. Percent Change of Estimated Glomerular Filtration Rate (eGFR) Values From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population

    eGFR was assessed using creatinemia and the Modification of Diet in Renal Disease (MDRD) study equation. eGFR were evaluated in terms of mean difference between the pre- and post-MRI procedure. The eGFR variation was expressed as a percentage of change from baseline values.

    Time frame: Baseline pre MRI and 3 days post MRI

  4. eGFR Values Variation Between Baseline and 72±24 Hours After Examination, in the Per Protocol Population

    eGFR (estimated Glomerular Filtration Rate) was assessed using creatinemia and the Modification of Diet in Renal Disease (MDRD) study equation. eGFR were evaluated in terms of mean difference between the pre- and post-MRI procedure. The eGFR variation was expressed as a percentage of change from baseline values.

    Time frame: Baseline pre MRI and 3 days post MRI

07

Results

Posted Jun 9, 2015

Participant flow

This study did not use randomization. Eligible patients who provided written consent were enrolled chronologically in each investigational center. A total of 142 patients were screened between 29 January 2008 and 05 May 2011, 135 of whom were included in 15 European centers, eight centers in France, three in Belgium, two in Spain and two in Italy.

Participant flow — Overall Study
MilestoneDotarem®-Enhanced MRINon-enhanced MRI
Started7557
Completed7044
Not completed513
Withdrew: Withdrawal by subject50
Withdrew: Protocol violation013

Outcome measures

PrimaryNumber of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis Set Population.

Comparing the number of patients experiencing an increase of creatinine of at least 25% over baseline levels after Dotarem®-enhanced MRI and after non-enhanced MRI in patients with at least a moderate renal insufficiency.

Time frame:
baseline pre MRI and 3 days post MRI
Reported as:
Number · Number of patients
Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis Set Population.
Number of patientsDotarem®-Enhanced MRINon-enhanced MRI
Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis Set Population.10
Statistical analysis
  • Dotarem®-Enhanced MRI vs Non-enhanced MRI · Mean difference (final values): -1.4 · 95% CI -7.9 to 6.7
SecondaryPercent Change of Serum Creatinine Level From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population.

Serum creatinine levels were measured at baseline and at 72±24 hours after examination. The percentage of change in creatinemia from baseline was calculated for both the Dotarem® and the non-enhanced groups.

Time frame:
Baseline pre MRI and 3 days post MRI
Reported as:
Mean · Percentage of change from baseline
Percent Change of Serum Creatinine Level From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population.
Percentage of change from baselineDotarem®-Enhanced MRINon-enhanced MRI
Percent Change of Serum Creatinine Level From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population.-1.40 ± 10.36-3.48 ± 9.92
Statistical analysis
  • Dotarem®-Enhanced MRI vs Non-enhanced MRI · t-test, 2 sided · p = 0.291 (p-value for main effect (difference between groups) adjusted on centers.)
PrimaryNumber of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of at Least 25% Over Baseline Levels, in the Per Protocol Population.

Comparing the number of patients experiencing an increase of creatinine of at least 25% over baseline levels after Dotarem®-enhanced MRI and after non-enhanced MRI in patients with at least a moderate renal insufficiency.

Time frame:
Baseline pre MRI and 3 days post MRI
Reported as:
Number · Number of patients
Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of at Least 25% Over Baseline Levels, in the Per Protocol Population.
Number of patientsDotarem®-Enhanced MRINon-enhanced MRI
Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of at Least 25% Over Baseline Levels, in the Per Protocol Population.10
Statistical analysis
  • Dotarem®-Enhanced MRI vs Non-enhanced MRI · Mean difference (final values): -2.7 · 95% CI -14.1 to 8.9
SecondaryPercent Change of Serum Creatinine Level Variation From Baseline to 72±24 Hours After Examination, in the Per Protocol Population

Serum creatinine levels were measured at baseline and at 72±24 hours after examination. The percentage of change in creatinemia from baseline was calculated for both the Dotarem® and the non-enhanced groups.

Time frame:
Baseline pre MRI and 3 days post MRI
Reported as:
Mean · Percentage of change from baseline
Percent Change of Serum Creatinine Level Variation From Baseline to 72±24 Hours After Examination, in the Per Protocol Population
Percentage of change from baselineDotarem®-Enhanced MRINon-enhanced MRI
Percent Change of Serum Creatinine Level Variation From Baseline to 72±24 Hours After Examination, in the Per Protocol Population0.05 ± 10.84-5.17 ± 9.16
Statistical analysis
  • Dotarem®-Enhanced MRI vs Non-enhanced MRI · t-test, 2 sided · p = 0.040 (p-value for main effect (difference between groups) adjusted on centers.)
SecondaryPercent Change of Estimated Glomerular Filtration Rate (eGFR) Values From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population

eGFR was assessed using creatinemia and the Modification of Diet in Renal Disease (MDRD) study equation. eGFR were evaluated in terms of mean difference between the pre- and post-MRI procedure. The eGFR variation was expressed as a percentage of change from baseline values.

Time frame:
Baseline pre MRI and 3 days post MRI
Reported as:
Mean · Percentage of change from baseline
Percent Change of Estimated Glomerular Filtration Rate (eGFR) Values From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population
Percentage of change from baselineDotarem®-Enhanced MRINon-enhanced MRI
Percent Change of Estimated Glomerular Filtration Rate (eGFR) Values From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population3.02 ± 12.515.55 ± 12.94
Statistical analysis
  • Dotarem®-Enhanced MRI vs Non-enhanced MRI · t-test, 2 sided · p = 0.301 (p-value for main effect (difference between groups) adjusted on centers.)
SecondaryeGFR Values Variation Between Baseline and 72±24 Hours After Examination, in the Per Protocol Population

eGFR (estimated Glomerular Filtration Rate) was assessed using creatinemia and the Modification of Diet in Renal Disease (MDRD) study equation. eGFR were evaluated in terms of mean difference between the pre- and post-MRI procedure. The eGFR variation was expressed as a percentage of change from baseline values.

Time frame:
Baseline pre MRI and 3 days post MRI
Reported as:
Mean · Percentage of change from baseline
eGFR Values Variation Between Baseline and 72±24 Hours After Examination, in the Per Protocol Population
Percentage of change from baselineDotarem®-Enhanced MRINon-enhanced MRI
eGFR Values Variation Between Baseline and 72±24 Hours After Examination, in the Per Protocol Population1.37 ± 12.657.58 ± 12.82
Statistical analysis
  • Dotarem®-Enhanced MRI vs Non-enhanced MRI · t-test, 2 sided · p = 0.051 (p-value for main effect (difference between groups) adjusted on centers.)

Adverse events

Collected over The period of observation for Adverse Events (AEs) collection extended from the time of patient informed consent until the end of his/her follow-up (i.e. 72 ±24hrs or 14 days after the imaging procedure) or until patient early withdrawal from the trial.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dotarem®-Enhanced MRI—0/70 (0%)6/70 (8.6%)
Non-enhanced MRI—0/44 (0%)0/44 (0%)
Most frequent other events
Most frequent other events
EventDotarem®-Enhanced MRINon-enhanced MRI
HematomaVascular disorders1/700/44
Abdominal pain upperGastrointestinal disorders1/700/44
HypotensionVascular disorders1/700/44
Blood creatinin increasedInvestigations1/700/44
toothacheGastrointestinal disorders1/700/44
ConstipationGastrointestinal disorders1/700/44

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dotarem®-Enhanced MRINon-enhanced MRITotal
Mean69.6 ± 11.566.2 ± 12.267.9 ± 12.0
Age, Categorical
Age, Categorical(Participants)Dotarem®-Enhanced MRINon-enhanced MRITotal
<=18 years000
Between 18 and 65 years242044
>=65 years513788
Sex: Female, Male
Sex: Female, Male(Participants)Dotarem®-Enhanced MRINon-enhanced MRITotal
Female242347
Male513485
Region of Enrollment
Region of Enrollment(participants)Dotarem®-Enhanced MRINon-enhanced MRITotal
France441155
Belgium14721
Spain172340
Italy01616
08

Study locations

15 sites
  • Onze Lievevrouwziekenhuis
    Aalst, 9300, Belgium
  • University Hospital Ghent
    Gent, 9000, Belgium
  • Alg. Inwendige Ziekten -Nierziekten
    Roeselare, 8800, Belgium
  • Groupe Hospitalier Pellegrin
    Bordeaux, 33076, France
  • Hôpital A. Calmette
    Lille, 59037, France
  • Hôpital Edouard Herriot
    Lyon, 69437, France
  • Hopital Pitie Salpetriere
    Paris, 75013, France
  • Hopital Bichat
    Paris, 75018, France
  • Hôpital Tenon
    Paris, 75020, France
  • CHU Strasbourg
    Strasbourg, 67000, France
  • Hôpital Trousseau
    Tours, 37044, France
  • Azienda Ospedaliera Universitaria di Ferrara
    Ferrara, 44100, Italy
  • Ente Ospedaliero Ospedali Galliera,
    Genova, 16128, Italy
  • Hospital San Carlos
    Madrid, 28040, Spain
  • Hospital Dr PESET
    Valencia, 46017, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of May 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2008
First posted
Apr 2, 2008
Start
Jan 2008
Primary completionActual
May 2011
CompletionActual
Aug 2011
Results first posted
Jun 9, 2015
Last update
Jun 9, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00650845
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Apr 2, 2008
Start date
Jan 2008
Primary completion
May 2011
Completion
Aug 2011
Results posted
Jun 9, 2015
Last update
Jun 9, 2015

Study contacts

Gilbert Deray, Pr, MD, PhD
principal investigator · Groupe Hospitalier Pitie-Salpetriere

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadoterate meglumine

Start the discussion